TGFBR2 and neoplasm: Critically, the immunosuppressive phenotype of TGFBR2High mGSCs is blocked by TGFBR2 inhibition, decreasing CD8+ T cell exhaustion and restoring CD4+ and CD8+ T cell tumor cell-killing ability in vitro (Figure 3, Figure 4 and Figure S3).